Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. reported revenue of RMB 685.80 million for the year ended December 31, 2025, reflecting a slight decline compared with the previous year. Operating profit recorded approximately RMB -155.40 million, and net profit attributable to ordinary shareholders stood at around RMB -157.44 million. According to the announcement, the company's research and development investments amounted to roughly RMB 358.00 million for the reporting period.

The decrease in profitability was largely influenced by adjustments to the sales strategy of its product LIBOd®, which reduced profit contributions by about RMB 100.00 million compared with the prior year. At the same time, higher R&D expenses—an increase of around RMB 44.00 million—impacted earnings. The announcement states that these figures are based on unaudited results and that final audited numbers will be disclosed in the official annual report.